Galectin Therapeutics (GALT) Notes Payables (2024 - 2025)
Galectin Therapeutics (GALT) posted quarterly Notes Payables of $3.7 million for Q3 2025, up 942.34% year-over-year from $359000.0 in Q3 2024, and up 1126.89% quarter-over-quarter from $305000.0 in Q1 2025.
Galectin Therapeutics (GALT) Notes Payables (2024 - 2025) Analysis & Trends
Galectin Therapeutics' Notes Payables history runs 2 years deep, the most recent figure standing at $3.7 million for Q3 2025.
- In Q3 2025, Notes Payables rose 942.34% year-over-year to $3.7 million; the TTM figure through Sep 2025 stood at $3.7 million (up 942.34% YoY), while the FY2024 annual figure was $369000.0, changed N/A from the prior year.
- Notes Payables for Q3 2025 stood at $3.7 million, up from $305000.0 in the prior quarter.
- The five-year high for Notes Payables was $3.7 million in Q3 2025, with the low at $305000.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Galectin Therapeutics | 226.55 Mn | 226.55 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 3.74 Mn |
| Mar 31, 2025 | 305,000.00 |
| Dec 31, 2024 | 369,000.00 |
| Sep 30, 2024 | 359,000.00 |